20.500.12556/ReVIS-13858 Socio-gerontological perspectives on introducing new Alzheimer’s therapies: a Delphi study across Central European care contexts Introduction: Disease-modifying therapies (DMTs) for Alzheimer’s disease, such as Lecanemab, represent a shift fromsymptomatic treatment toward disease modification. Their implementation raises broader societal, ethical, and systemicchallenges related to early diagnosis, healthcare preparedness, long-term care adaptation, and equitable access to treatment.Aim: This study explored expert perspectives on the societal, ethical, and systemic implications of introducing disease-modifying Alzheimer’s therapies within Central European healthcare and long-term care contexts.Methods: A three-round modified Delphi study combining qualitative and quantitative elements was conducted with tenmultidisciplinary experts from Slovenia, Austria, and Bosnia and Herzegovina. Data were collected through anonymisedonline questionnaires and analysed using thematic analysis, descriptive statistics, and Kendall’s coefficient of concordance(W).Results: The Delphi process identified six highly prioritised themes: (1) public and professional awareness and education(M = 9.71), (2) development of tailored long-term care models (M = 9.71), (3) faster access to innovative therapies (M =9.43), (4) reduction of dementia-related stigma through public dialogue (M = 8.57), (5) consideration of cultural beliefsand healthcare funding (M = 8.29), and (6) accessibility of medications despite pricing strategies (M = 8.29). Kendall’scoefficient indicated low statistical agreement among expert rankings (W =.084), suggesting partial alignment regardingthematic priorities rather than strong consensus.Conclusion: The findings suggest that implementing disease-modifying Alzheimer’s therapies represents not only a biomed-ical innovation but also a broader socio-gerontological and health system challenge. Alzheimer’s disease Lecanemab Delphi method long-term care health equity social gerontology Alzheimerjeva bolezen Lecanemab Delphi-metoda dolgotrajna oskrba enakost v zdravju socialna gerontologija true false false Angleški jezik Slovenski jezik Neznano 2026-05-19 15:04:54 2026-05-19 15:04:55 2026-05-20 03:19:47 0000-00-00 00:00:00 2026 0 0 Nasl. z nasl. zaslona; Opis vira z dne 19. 5. 2026; 9 str. no. 1 Vol. 5 jan.-jun. 2026 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 0000-00-00 2026-01-01 616.894:615.8:614:17(497.4+436+497.6) 2820-5480 278684163 10.33700/jhrs.5.1.222 https://jhrs.almamater.si/jhrs/issue/view/8 1 55a47334-5383-11f1-8a5a-001a4af901a5 https://revis.openscience.si/Dokument.php?lang=slv&id=16787 20126-Socio-Gerontological+Perspectives+on+Disease-Modifying+Alzheimer’s+Therapies+(Lecanemab)+A+Delphi+Study+in+Central+Europe.pdf 20126-Socio-Gerontological+Perspectives+on+Disease-Modifying+Alzheimer’s+Therapies+(Lecanemab)+A+Delphi+Study+in+Central+Europe.pdf 1 C6B709A50F8462408B736CE631758260 67d898c005342ff929b7f871495f57ca45835c61137697bb18a0cac07227e258 7b009245-5383-11f1-8a5a-001a4af901a5 https://revis.openscience.si/Dokument.php?lang=slv&id=16788 Univerza Alma Mater Europaea 0 0 0